Revance Therapeutics, Inc. — Form D/A
Revance Therapeutics, Inc. of NEWARK, CA, a company, filed a Form D amendment with the SEC on 2013-01-09. The offering totals $63.4M, of which $63.4M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2013-01-09
- Form: D/A
- Accession: 0001479290-13-000001
- Industry: Pharmaceuticals
- Exemptions: 06
- Total offering: $63.4M
- Amount sold: $63.4M
- Investors: 33
- Date of first sale: 2011-01-24
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-154773
Issuer
- Name: Revance Therapeutics, Inc.
- CIK: 0001479290
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 7555 GATEWAY BLVD., NEWARK, CA, 94560
- Phone: 510-742-3400
Officers, directors & promoters (19)
| Name | Role | Location |
|---|
| Ron Daniel Eastman | Director | Newark, CA |
| Ronald L Eastman | Director | Newark, CA |
| Frank L Kung | Director | Newark, CA |
| Phyllis L Gardner | Director | Newark, CA |
| Jonathan L Tunnicliffe | Director | Newark, CA |
| Daniel L Browne | Director | Newark, CA |
| Daniel L Browne | Executive Officer | Newark, CA |
| Vicente L Trelles | Director | Newark, CA |
| Robert L Byrnes | Director | Newark, CA |
| Jim L Glasheen | Director | Newark, CA |
| Vicente Daniel Trelles | Director | Newark, CA |
| Robert Daniel Byrnes | Director | Newark, CA |
| Phyllis Daniel Gardner | Director | Newark, CA |
| Frank Daniel Kung | Director | Newark, CA |
| Jim Daniel Glasheen | Director | Newark, CA |
| Jonathan Daniel Tunnicliffe | Director | Newark, CA |
| Ronald Daniel Eastman | Director | Newark, CA |
| L. Daniel Browne | Director | Newark, CA |
| L. Daniel Browne | Executive Officer | Newark, CA |
Other filings by this issuer (10)
More